内皮缩血管肽类

摘要： 目的 探究辛伐他汀辅助治疗蛛网膜下腔出血(SAH)的有效性及安全性.方法 选取我院2017年1月—2018年8月收治的SAH患者91例,随机分为对照组(47例)及试验组(44例),对照组给予常规治疗,试验组在常规治疗基础上加用辛伐他汀进行辅助治疗,比较两组患者治疗前后脑脊液和血清中炎症相关因子、内皮素(ET)、一氧化氮(NO)水平及神经功能、不良反应情况.结果 最终两组各43例患者完成该研究,两组不良反应发生率比较差异无显著性(P>0.05).治疗前两组患者脑脊液中白细胞介素6(IL-6)、基质金属蛋白酶2水平,血清中IL-6、肿瘤坏死因子α、IL-17、ET、NO、S100-β水平及NIHSS评分比较,差异均无显著性(P>0.05);治疗后两组中上述指标与治疗前比较,均显著降低(t=2.114～30.531,P0.05).结论 辛伐他汀辅助治疗SAH能有效缓解患者炎症反应,改善患者血管及神经功能,且安全性较好.

摘要： 目的探究辛伐他汀辅助治疗蛛网膜下腔出血(SAH)的有效性及安全性。方法选取我院2017年1月—2018年8月收治的SAH患者91例,随机分为对照组(47例)及试验组(44例),对照组给予常规治疗,试验组在常规治疗基础上加用辛伐他汀进行辅助治疗,比较两组患者治疗前后脑脊液和血清中炎症相关因子、内皮素(ET)、一氧化氮(NO)水平及神经功能、不良反应情况。结果最终两组各43例患者完成该研究,两组不良反应发生率比较差异无显著性(P>0.05)。治疗前两组患者脑脊液中白细胞介素6(IL-6)、基质金属蛋白酶2水平,血清中IL-6、肿瘤坏死因子α、IL-17、ET、NO、S100-β水平及NIHSS评分比较,差异均无显著性(P>0.05);治疗后两组中上述指标与治疗前比较,均显著降低(t=2.114~30.531,P0.05)。结论辛伐他汀辅助治疗SAH能有效缓解患者炎症反应,改善患者血管及神经功能,且安全性较好。

摘要： 目的 探讨颅内血肿微创清除术治疗脑出血(ICH)患者的临床效果.方法 选取2015年3月至2016年3月该院收治的高血压ICH患者120例作为研究对象,采用随机数字表法分为观察组和对照组,每组60例.对照组采用传统开颅手术治疗,观察组采用颅内血肿微创清除术治疗,比较两组患者手术前后血肿体积变化、血浆内皮素(ET)水平变化和治疗有效性.结果 两组患者术前血肿体积、血浆ET水平比较,差异均无统计学意义(P>0.05);观察组患者术后2周血肿体积、血浆ET水平均明显低于对照组,总有效率明显高于对照组,差异均有统计学意义(P<0.05).结论 高血压ICH患者采用颅内血肿微创清除术治疗可显著提升疗效,维持患者心血管系统稳态,挽救患者生命,值得推广应用.

摘要： 目的 观察β受体阻滞剂对小儿扩张型心肌病(DCM)的疗效.方法 对1995年至2015年在该院住院的DCM患儿61例进行回顾性分析,根据是否服用β受体阻滞剂,将患儿分为治疗组(服用β受体阻滞剂,n=35)和对照组(未服用β受体阻滞剂,n=26),初步观察β受体阻滞剂的疗效.结果 治疗后,治疗组心率、左心室舒张末期内径(LVDD)、左心室收缩末期内径(LVSD)、左心房内径(LA)较治疗前明显降低,射血分数(EF)明显升高(P＜0.05);对照组治疗后LVDD明显降低(P＜0.05),心率、右心室内径(RV)、LVDD、LVSD、LA、二尖瓣口血流速度(MV)及EF与入院前比较无明显变化(P＞0.05).治疗后,治疗组心率、LVDD、LVSD、EF与对照组比较差异有统计学意义(P＜0.05),治疗组心功能较对照组明显改善(P＜0.05).治疗组中伴有高血压的患儿心功能改善程度明显好于血压正常患儿(P＜0.05).治疗组中经卡维地洛治疗的患儿心功能改善程度明显好于美托洛尔治疗的患儿(P＜0.05).结论 β受体阻滞剂可用于小儿DCM的治疗,对伴有高血压的DCM患儿疗效更佳,其中卡维地洛比美托洛尔疗效更加优秀.%Objective To observe the effect of β-blocker on dilated cardiomyopathy (DCM) in children.Methods Sixty-one children cases of DCM in this hospital from 1995 to 2015 were retrospectively analyzed and divided into the treatment group(taking β-blocker,n=35) and control group(non-taking β-blocker,n=26) according to whether taking β-blocker.The clinical effect of β-blocker was preliminarily observed.Results The heart rate,LVDD,LVSD and LA after treatment in the treatment group were significantly decreased compared with before treatment(P＜0.05),while EF was significantly increased(P＜0.05);LVDD after treatment in the control group was significantly decreased(P＜0.05),while hear rate,RV,LVDD,LVSD,LA,MV and EF had no obvious change compared with before admission(P＞0.05).The heart rate,LVDD,LVSD and EF after treatment had statistical difference between the treatment group and control group (P＜0.05),the heart function after treatment in the treatment group was significantly improved compared with the control group (P＜0.05).The heart function improvement degree after treatment in the patients with hypertension of the treatment group was significantly better than those with normal blood pressure(P＜0.05).DCM with hypertension was significantly improved after treatment and was better than DCM without hypertension (P＜0.05).The The heart function improvement degree after treatment in the patients with carvedilol treatment was obviously better than that in the patients with metoprolol treatment(P＜0.05).Conclusion β-blocker could be used in the treatment of DCM,its effect is especially good in DCM children patients with hypertension,in which the effect of carvedilol is better than that of metoprolol.

摘要： 背景：血管内皮细胞在凝血过程中能够分泌众多凝血物质参与凝血级联反应或收缩血管促进凝血进程。目的：综述血管内皮细胞分泌的不同凝血物质的作用机制,为凝血功能材料的筛选提供理论依据。方法：应用计算机检索中国知网、Pub Med数据库1988至2016年收录的与血管内皮细胞凝血物质相关的文献。英文检索词为＂Vascular endothelial cells,endothelin,AngⅡ,TXA2,tissue factor,Collagen,fibronectin,von wilbrand factor,thrombospondin,platelet activating factor,plasminogen activator inhibitor,proaccelerin,antihemophlic factor＂,中文检索词为＂血管内皮细胞,组织因子,胶原,纤维连接蛋白,血小板激活因子,纤溶酶原激活物抑制物,凝血因子Ⅴ、Ⅷ,内皮素,血管紧张素Ⅱ,血栓素＂,最终纳入文献38篇进行综述。结果与结论：血管损伤时血管内皮细胞产生的众多凝血因子在凝血、炎症反应以及血栓形成过程中发挥着重要的作用。凝血过程中,血管内皮细胞分泌众多促凝因子和凝血因子Ⅴ和Ⅷ直接参与凝血级联瀑布反应,促进血栓形成;同时血管内皮细胞分泌的收缩血管因子使血管腔狭小,辅助凝血过程,间接促进血栓形成。

摘要： Objective]To study the changes of endothelin (ET)and the von Willebrand factor (vWF)before and af-ter interventional therapy in patients with coronary heart disease and the use of the two variables in predicting the presence of postoperative complications.[Methods]Two hundred and seventy-three patients with coronary heart disease in our hos-pital from January 2014 to January 2010 were selected,and the levels of serum ET and vWF were carefully monitored at certain time intervals.Additionally,the presence of postoperative complications after one year were compared with the changes of serum ET and vWF to find any correlation.[Results]Serum ET and vWF levels in the Acute Myocardia Infarc-tion (AMI)group,Unstable Angina Pectoris (UAP)group,and Stable Angina Pectoris (SAP)group before surgery,30 minutes after,and 24 hours after surgery were all significantly higher than those of the control group.The difference was statistically significant (all P <0.05).The serum Et and vWF levels in the AMI,UAP,SAP groups before surgery,30 minutes after,24 hours after,and three days after surgery were presented first as increasing and then decreasing.,The serum ET level reached its peak 30 min after the surgery while the serum vWF level peaks at 24 hours after the surgery. Peak levels of serum ET and vWF in patients with complications were significantly higher than the peak levels in the pa-tients without complications (P <0.05).Logistic regression analysis of hypertension (RR = 1.752,P =0.033),diabe-tes (RR = 1.325,P =0.038),preoperative ET level (RR = 2.896,P =0.041),and preoperative vWF levels (RR =2.336,P =0.035)were statistically significant (P <0.05)in predicting PCI complications.[Conclusion]Endothelin and the von Willebrand factor can reflect the damage of endothelium to provide value for predicting the presence of postopera-tive complications in patients with coronary heart disease..%【目的】研究冠心病患者行经皮冠状动脉介入术(PCI)前后内皮素(ET)、血管性假血友病因子(vWF)的变化以及对术后并发症的预测价值。【方法】选择2010年1月至2014年1月本院心内科住院收治的273例行PCI 治疗的冠心病患者,比较其不同时间点血清 ET、vWF 水平变化,并观察研究对象术后1年内并发症发生情况与血清 ET、vWF 水平的相关性。【结果】急性心肌梗死(AMI)组,不稳定型心绞痛(UAP)组,稳定型心绞痛(SAP)组术前、术后30 min 以及术后24 h 血清 ET、vWF 水平均显著高于对照组,差异均有统计学差异(均 P <0.05)；AMI 组、UAP 组、SAP 组术前、术后30 min、术后24 h、术后3 d 血清 ET、vWF 水平均呈现先升高后降低态势,其中血清 ET 水平术后30 min 为峰值,血清 vWF 水平术后24 h 为峰值；PCI 术后发生并发症患者血清 ET、vWF 峰值水平显著高于无并发症患者,差异有统计学意义(P <0.05)。logstic 回归分析显示高血压(RR=1.752,P =0.033)、糖尿病(RR=1.325,P =0.038)、术前 ET 水平(RR=2.896,P =0.041)、术前 vWF 水平(RR=2.336,P =0.035)是 PCI 术后并发症的高危因素。【结论】血清 ET、vWF 水平可反映 PCI 术后患者内皮损伤情况,对患者预后评估有重要的临床应用价值。

摘要： Objective To observe the therapeutic effects of Qufeng-qingre-dingtong decoction in migraine rats and its possible mechanism.Methods 72 SD rats were randomly divided into six groups, that the blank group, model group, Zhengtian pill group, and high, middle, low dose of Qufeng -qingre -dingtong decoction group. Twelve SD rats in each groups, and all rats received corresponding drug for 7 d by gavage.Besides blank group, rats in other five groups were constructed in migraine model by nitroglycerin after the pain-threshold measured by hot plate test.The contents of serum endothelin-1 (ET-1) and 5-hydroxytryptamine (5-HT) were detected by ra-dioimmunoassay.Results Compared with model group over the same period, the pain-threshold in high, middle dose of Qufeng-qingre-dingtong decoction group were obviously increased at 60, 120, 180 min (P0.05).Compared with high dose of Qufeng-qingre-dingtong decoction group, there was statistical significance on ET-1 and 5-HT in middle dose group (P0.05).Conclusion Qufeng-qingre-dingtong decoction has significant analgesic effect, can regulate the contents of serum 5-HT, ET-1 in migraine rats, it could be the one of the analgesia mechanism.%目的：观察祛风清热定痛方对偏头痛大鼠的镇痛效应及可能机制。方法将72只SD大鼠随机分为6组，即空白组、模型组、正天丸组和祛风清热定痛方大、中、小剂量组，每组各12只，分别予相应药液灌胃给药，连续7d。除空白组外，其余5组大鼠通过热板法测定痛阈值，然后以硝酸甘油制备偏头痛大鼠模型，放免法检测各组大鼠血浆中内皮素1（ET－1）、5－羟色胺（5－HT）含量。结果与模型组同期比较，祛风清热定痛方大、中剂量组60、120、180 min痛阈值均显著提高（P＜0．05），祛风清热定痛方小剂量组、正天丸组120、180 min痛阈值均显著提高（P＜0．05）。与模型组比较，祛风清热定痛方大、中、小剂量组及正天丸组ET－1含量均明显降低，5－HT含量均明显增加，比较差异有统计学意义（ P＜0．05）。与正天丸组比较，祛风清热定痛方大、中剂量组ET－1含量明显降低，5－HT含量明显增加，差异有统计学意义（P＜0．05），小剂量组ET－1和5－HT含量无统计学意义（ P＞0．05）。与祛风清热定痛方大剂量组相比，祛风清热定痛方中剂量组ET－1和5－HT含量比较差异有统计学意义（P＜0．05），小剂量组无统计学意义（P＞0．05）。结论祛风清热定痛方具有明显的镇痛作用，其调节偏头痛模型大鼠血浆5－HT、ET－1含量可能是治疗偏头痛的机制之一。

摘要： 目的：评价黄连解毒汤加味治疗顽固性高血压的疗效。方法本研究为随机对照研究。将符合纳入标准的90例顽固性高血压患者按随机数字表分为2组各45例，对照组口服厄贝沙坦氢氯噻嗪片和硝苯地平控释片治疗，治疗组在对照组基础上联合应用黄连解毒汤加味。共4周。采用放射免疫法检测血浆内皮素(endothelin, ET)、降钙素基因相关肽(calcitonin gene related peptide, CGRP)以探讨药物的作用机制。结果治疗组与对照组证候疗效总有效率分别为86.7%(29/45)、64.4%(39/45)，2组比较差异有统计学意义(χ2＝4.873， P＝0.027)。治疗后，治疗组收缩压[(119.26±9.34)mmHg 比(172.11±10.52)mmHg，t＝25.201]、舒张压[(78.18±7.21)mmHg比(111.12±11.16)mmHg，t＝16.631]；对照组收缩压[(145.21±7.56)mmHg比(171.32±11.15)mmHg，t＝13.002]、舒张压[(93.57±8.13)mmHg比(109.89±12.21)mmHg，t＝7.463]均较同组治疗前降低(P＜0.01)，且治疗组收缩压、舒张压均低于对照组(t 值分别为14.487、9.501，P＜0.01)。治疗组与对照组降压疗效总有效率分别为73.3%(33/45)、55.6%(25/45)，2组比较差异无统计学意义(χ2＝2.376，P＝0.123)。治疗组ET[(75.68±10.67)ng/L比(112.79±12.26)ng/L， t＝15.317]较对照组降低(P＜0.05)，CGRP [(49.87±4.75)ng/L比(33.87±7.89)ng/L，t＝11.654]较对照组升高(P＜0.05)。结论黄连解毒汤可有效治疗顽固性高血压，其机制可能与降低血浆ET和升高CGRP水平有关。%Objective To evaluate the therapeutic effect of modifiedHuanglian-Jiedudecoction for resistant hypertension and explore its possible mechanism.Methods A total of 90 patients with resistant hypertension were recruited and randomly divided into a treatment group and a control group, 45 patients in each group. The control group was treated with oral administration of irbesartan and hydrochlorothiazide tablets and controlled-release nifedipine tablets, while the treatment group was further added modifiedHuanglian-Jiedu decoction for 4 weeks. Plasma endothelin (ET) and calcitonin gene-related peptide (CGRP) were measured by radioimmunoassay.Rusults The total efficiency according to the TCM syndrome in the treatment group was 86.7%(39/45) which was higher than 64.4%(29/45) in the control group(χ2=4.873,P=0.027). The systolic blood pressure (SBP) and diastolic blood pressure (DBP) decreased after the treatment in both groups ( SBP in the treatment group: 119.26 ± 9.34 mmHgvs.172.11 ± 10.52 mmHg,t=25.201,P<0.01; DBP in the treatment group: 78.18 ± 7.21 mmHgvs.111.12 ± 11.16 mmHg,t=16.631, P<0.01; SBP in the control group: 145.21 ± 7.56 mmHgvs.171.32 ± 11.15 mmHg,t=13.002,P<0.01; DBP in the control group: 93.57±8.13 mmHgvs. 109.89 ± 12.21 mmHg,t=7.463,P<0.01), while the decrease of SBP (t=14.487,P<0.01) and DBP (t=9.501, P<0.01) in the treatment group was more greater than those in the control group. The control rate of blood pressure in the treatment and control groups were 73.3% (33/45) and 55.6% (25/45), respectively, there had no significant difference (χ2=2.376,P=0.123). The plasma ET in the treatment group was significantly decreased than that in the control group (75.68 ± 10.67 ng/Lvs.112.79 ± 12.26ng/L;t=15.317,P<0.05), and CGRP significantly increased (49.87 ± 4.75 ng/Lvs.33.87 ± 7.89 ng/L;t=11.654,P<0.05).Conclusion Modified Huanglian-Jiedudecoction may have some therapeutic effect for resistant hypertension, its mechanism may be involved in ET decreasing and CGRP increasing.

摘要： 目的 探讨肾去交感神经(RSD)对肺动脉高压(PAH)模型犬肺血管重构的影响.方法 24只比格犬按随机数字表法随机均分为对照组、PAH组、PAH+ RSD组各8只.检测各组犬实验前血清神经激素水平、心脏超声和血流动力学参数后,对照组右心房注入二甲基甲酰胺(0.1 ml/kg),PAH组右心房注入脱氢野百合碱(2 ml/kg),PAH+ RSD组先行肾去交感神经术,后右心房注入脱氢野百合碱(2 ml/kg).喂养8周,检测各组犬实验后的血清神经激素水平、心脏超声和血流动力学参数后,开胸取肺组织检测肺血管形态学.结果 实验后PAH组、PAH+ RSD组右心室收缩压(RVSP)和肺动脉收缩压(PASP)均显著高于对照组[(42.8±8.7)、(30.8±6.8)比(23.2±5.7) mmHg(1mmHg =0.133 kPa)和(45.1±11.2)、(32.6±7.9)比(24.7 ±7.1)mmHg],且PAH组RVSP和PASP显著高于PAH+ RSD组[均P＜0.01].实验后PAH组血清血管紧张素Ⅱ(AngⅡ)和内皮素1水平均显著高于实验前[(228 ±41)比(113±34) pg/ml和(135 ±15)比(77±7)pg/ml,均P＜0.01],且肺组织中AngⅡ和内皮素1水平[(65±10)和(96±10)pg/ml]均显著高于对照组[(38±7)和(54±6)pg/ml]和PAH+ RSD组[(46±8)和(67±9)pg/ml](均P＜0.01).与对照组相比,PAH组肺泡2型细胞破坏严重,组织纤维化明显,而PAH+ RSD组肺泡2型细胞破坏及组织纤维化较PAH组轻.结论 RSD可降低PAH模型犬肺动脉高压并抑制肺血管重构,此作用可能与其降低神经激素水平有关.%Objective To explore the effects of renal sympathetic denervation (RSD) on pulmonary vascular remodeling in a model of pulmonary arterial hypertension (PAH).Methods According to the random number table,24 beagles were randomized into control,PAH and PAH + RSD groups (n =8 each).The levels of neurohormone,echocardiogram and dynamics parameters were measured.Then 0.1 ml/kg dimethylformamide (control group) or 2 mg/kg dehydromonocrotaline (PAH and PAH + RSD groups) were injected.The PAH + RSD group underwent RSD after injection.At week 8 post-injection,the neurohormone levels,echocardiogram,dynamics parameters and pulmonary tissue morphology were observed.Results The values of right ventricular systolic pressure (RVSP) and pulmonary arterial systolic pressure (PASP) in PAH and PAH + RSD groups were both significantly higher than those in control group ((42.8 ± 8.7),(30.8±6.8) vs (23.2±5.7) mmHg (1 mmHg=0.133 kPa) and (45.1 ±11.2),(32.6±7.9) vs (24.7 ±7.1) mmHg).Meanwhile,the values of RVSP and PASP in PAH group were higher than those in PAH + RSD group (all P ＜ 0.01).The levels of serum angiotensin Ⅱ (Ang Ⅱ) and endothelin-1 significantly increased after 8 weeks in PAH dogs ((228 ± 41) vs (113 ± 34) pg/ml and (135 ± 15) vs (77 ±7) pg/ml,all P ＜0.01).And Ang Ⅱ and endothelin-1 were higher in lung tissues of PAH group ((65 ± 10)and (96 ± 10) pg/ml) than in those of control group ((38 ± 7) and (54 ± 6) pg/ml) and PAH + RSD group ((46 ± 8) and (67 ± 9) pg/ml) (all P ＜ 0.01).Pulmonary tissues had marked collagen hyperplasia and lamellar corpuscles of type 2 alveolar cells were damaged more severely in PAH dogs than in PAH + RSD dogs.Conclusions RSD suppresses pulmonary vascular remodeling and decreases pulmonary arterial pressure in experimental PAH.And the effect of RSD on PAH may contribute to decreased neurohormone levels.

摘要： 目的：研究高糖血症时胰岛素对内皮素-1(ET-1)缩血管作用的影响。方法：复制高糖血症大鼠模型；将高糖大鼠和正常大鼠的离体主动脉血管环置于无胰岛素和高于生理浓度(40 mIU/L)胰岛素的KH液中，观察两组大鼠血管对10 mol/L ET-1的反应。结果：高糖大鼠血管对ET-1的反应明显弱于正常大鼠(P<0.01)；高浓度胰岛可减弱ET-1对正常大鼠血管的收缩作用(P<0.01)；胰岛素不能减弱ET-1对高糖大鼠血管的收缩作用。结论：(1)长期高糖血症使血管对ET-1的反应降低；(2)胰岛素可减弱ET-1对正常大鼠血管的收缩作用；(3)长期高糖血症使胰岛素对ET-1缩血管活性的影响减小。

摘要： 目的：研究高糖血症时胰岛素对内皮素-1(ET-1)缩血管作用的影响。方法：复制高糖血症大鼠模型；将高糖大鼠和正常大鼠的离体主动脉血管环置于无胰岛素和高于生理浓度(40 mIU/L)胰岛素的KH液中，观察两组大鼠血管对10 mol/L ET-1的反应。结果：高糖大鼠血管对ET-1的反应明显弱于正常大鼠(P<0.01)；高浓度胰岛可减弱ET-1对正常大鼠血管的收缩作用(P<0.01)；胰岛素不能减弱ET-1对高糖大鼠血管的收缩作用。结论：(1)长期高糖血症使血管对ET-1的反应降低；(2)胰岛素可减弱ET-1对正常大鼠血管的收缩作用；(3)长期高糖血症使胰岛素对ET-1缩血管活性的影响减小。

摘要： 目的：研究高糖血症时胰岛素对内皮素-1(ET-1)缩血管作用的影响。方法：复制高糖血症大鼠模型；将高糖大鼠和正常大鼠的离体主动脉血管环置于无胰岛素和高于生理浓度(40 mIU/L)胰岛素的KH液中，观察两组大鼠血管对10 mol/L ET-1的反应。结果：高糖大鼠血管对ET-1的反应明显弱于正常大鼠(P<0.01)；高浓度胰岛可减弱ET-1对正常大鼠血管的收缩作用(P<0.01)；胰岛素不能减弱ET-1对高糖大鼠血管的收缩作用。结论：(1)长期高糖血症使血管对ET-1的反应降低；(2)胰岛素可减弱ET-1对正常大鼠血管的收缩作用；(3)长期高糖血症使胰岛素对ET-1缩血管活性的影响减小。

摘要： 目的：研究高糖血症时胰岛素对内皮素-1(ET-1)缩血管作用的影响。方法：复制高糖血症大鼠模型；将高糖大鼠和正常大鼠的离体主动脉血管环置于无胰岛素和高于生理浓度(40 mIU/L)胰岛素的KH液中，观察两组大鼠血管对10 mol/L ET-1的反应。结果：高糖大鼠血管对ET-1的反应明显弱于正常大鼠(P<0.01)；高浓度胰岛可减弱ET-1对正常大鼠血管的收缩作用(P<0.01)；胰岛素不能减弱ET-1对高糖大鼠血管的收缩作用。结论：(1)长期高糖血症使血管对ET-1的反应降低；(2)胰岛素可减弱ET-1对正常大鼠血管的收缩作用；(3)长期高糖血症使胰岛素对ET-1缩血管活性的影响减小。

摘要： 本发明公开了使用ET

摘要： 本发明描述了用于心血管疾病、特别是原发性高血压、肺动脉高压和/或充血性心力衰竭的新联合疗法，包括给予至少一种中性肽链内切酶抑制剂、至少一种内源性内皮缩血管肽产生系统抑制剂和至少一种AT1受体拮抗剂的协同组合。

摘要： 本发明提供被认为与高血压、伯格(Buerger)氏病、哮喘、眼底病及类似病症有关的内皮缩血管肽拮抗剂。即15-酮基-前列腺素E类化合物内皮缩血管肽拮抗剂，特别是13，14-二氢-15-酮基-16-单或二卤素-前列腺素。

摘要： 在再狭窄、肾衰竭和肺动脉高血压的治疗中有用的式(I)化合物，及它们的药学上可接受的衍生物，其中R

摘要： 本发明公开了使用ET

摘要： 一般而言，本发明涉及包含内皮缩血管肽A受体(ET

摘要： 本发明描述了用于心血管疾病、特别是原发性高血压、肺动脉高压和/或充血性心力衰竭的新联合疗法，包括给予至少一种中性肽链内切酶抑制剂、至少一种内源性内皮缩血管肽产生系统抑制剂和至少一种AT

摘要： 本发明涉及抑制骨转移的方法、预防新的骨转移灶生长的方法、抑制骨更新的方法、以及预防患者骨损失的方法，其中所说的患者包括癌症患者，该方法包括使用一种内皮缩血管肽ET－A受体拮抗剂。

摘要： 本发明公开了一种检测原发性高血压易感性的方法，它包括检测个体的内皮缩血管肽1基因EDN1、转录本和/或蛋白与正常相比是否存在变异，存在变异就表明该个体患原发性高血压的可能性大于正常人群。本发明还公开了相应的检测试剂盒。

摘要： 本发明涉及式(Ⅰ)的羧酸衍生物,其中,取代基具有下列含义:R